Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
Actinogen Medical’s lead program for its sole pipeline candidate has failed a late-stage study, but the Australian biotech still plans on taking the findings to the FDA for a path forward.
comments(0)
5-min edit window · permanent after that